
Opinion|Videos|November 19, 2025
Ongoing Research to Watch in TNBC
Panelists spotlight key trials and drugs to watch in ongoing research in triple-negative breast cancer.
Advertisement
Episodes in this series

The panel concludes by highlighting pivotal ongoing trials and investigational agents shaping the future of TNBC care. Areas of focus include next-generation ADCs, bispecific antibodies, and novel immunotherapy combinations designed to overcome resistance. Panelists also underscore the need for improved biomarker discovery, especially to identify which patients benefit most from immunotherapy or ADC-based regimens. They note that the TNBC research field is entering a dynamic phase where rational combination strategies and earlier intervention with effective agents could significantly improve patient outcomes.
Advertisement
Related to this article

Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.

Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.

A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.

The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.

The HER2-directed ADC produced confirmed responses across both biomarker-defined cohorts of advanced salivary gland carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
4
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
5

